Oppenheimer Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $7
Wells Fargo Upgrades Regulus Therapeutics(RGLS.US) to Buy Rating, Raises Target Price to $6
Regulus Therapeutics Analyst Ratings
Wells Fargo Upgrades Regulus Therapeutics to Overweight From Equalweight, $6 Price Target; Share Rise
Canaccord Genuity Maintains Buy on Regulus Therapeutics, Maintains $28 Price Target
H.C. Wainwright Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $10
Regulus Therapeutics Analyst Ratings
H.C. Wainwright Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $10
Regulus Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $10 Price Target
JonesTrading Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $8
Oppenheimer Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $7
H.C. Wainwright Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $10
Regulus Therapeutics Poised for Growth: Promising ADPKD Study Results and Strategic Milestones Drive Buy Rating
Buy Rating for Regulus Therapeutics Driven by Promising Clinical and Regulatory Prospects for RGLS8429
Regulus Therapeutics Analyst Ratings
H.C. Wainwright Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $10
H.C. Wainwright Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $10
Regulus Therapeutics Analyst Ratings
Oppenheimer Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $7